SCORE2 Report 2: Study Design and Baseline Characteristics.

ABSTRACT:

Purpose

To describe the design and baseline characteristics of participants in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with cohorts from other retinal vein occlusion trials.

Design

Phase III prospective, multicenter, randomized clinical trial designed to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased vision attributable to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).

Participants

Total of 362 participants: 307 with CRVO and 55 with HRVO.

Methods

Demographic and study eye characteristics are summarized and compared between CRVO and HRVO study participants.

Main outcome measures

Baselin

SUBMITTER: Scott IU 

PROVIDER: S-EPMC5272814 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature